Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.

NCT02225548 is registered in ClinicalTrials.gov with University of South Florida as lead sponsor.

NCT NCT02225548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02225548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.
Lead sponsor
University of South Florida
Phase
Phase 4
Overall status
Unknown status
Start date
September 30, 2014
Completion date
January 31, 2019
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erectile dysfunction, parkinson's disease